INCREASE研究生存分析:吸入曲前列尼尔对PH-ILD总死亡率的影响及治疗交叉效应评估
该研究对INCREASE试验及其开放标签扩展(OLE)进行事后分析,采用IPCW和RPSFT两种模型构建伪安慰剂组,评估吸入曲前列尼尔对间质性肺病相关肺动脉高压(PH-ILD)患者的长期生存获益。常规分析HR为0.71(95%CI 0.46-1.10;p=0.1227),而IPCW和RPSFT模型分别显示HR 0.62(95%CI 0.39-0.99;p=0.0483)和0.26(95%CI 0.07-0.98;p=0.0473),提示长期生存获益。
要点
- 常规分析未显示显著生存获益,HR 0.71(95%CI 0.46-1.10;p=0.1227)。
- IPCW模型显示显著获益,HR 0.62(95%CI 0.39-0.99;p=0.0483)。
- RPSFT模型显示显著获益,HR 0.26(95%CI 0.07-0.98;p=0.0473)。
核心结论
- 两种独立建模方法均提示吸入曲前列尼尔治疗与PH-ILD患者长期生存获益相关。
研究设计与样本
- 对INCREASE试验及其开放标签扩展(OLE)进行事后分析,采用IPCW和RPSFT模型构建伪安慰剂组。
- 随机试验期16周,吸入曲前列尼尔组死亡10例,安慰剂组死亡12例。
- OLE期间所有患者接受吸入曲前列尼尔,既往吸入曲前列尼尔组死亡29例,既往安慰剂组死亡33例。
主要发现
- 常规分析死亡HR为0.71(95%CI 0.46-1.10;p=0.1227)。
- IPCW模型死亡HR为0.62(95%CI 0.39-0.99;p=0.0483)。
- RPSFT模型死亡HR为0.26(95%CI 0.07-0.98;p=0.0473)。
临床怎么用
- 对于PH-ILD患者,吸入曲前列尼尔可能带来长期生存获益,但需结合个体情况评估。
局限性
- 为事后分析,常规分析未达统计学显著,模型结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A post-hoc analysis of the INCREASE trial and its open-label extension (OLE) was performed to evaluate whether inhaled treprostinil has a long-term survival benefit in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). METHODS: Two different models of survival were employed; the inverse probability of censoring weighting (IPCW) and the rank-preserving structural failure time (RPSFT) models both allow construction of a pseudo-placebo group, thereby allowing for long-term survival evaluation of patients with PH-ILD receiving inhaled treprostinil. Time-varying stabilised weights were calculated by fitting Cox proportional hazards models based on the baseline and time-varying prognostic factors to generate weighted Cox regression models with associated adjusted HRs. RESULTS: In the INCREASE trial, there were 10 and 12 deaths in the inhaled treprostinil and placebo arms, respectively, during the 16-week randomised trial. During the OLE, all patients received inhaled treprostinil and there were 29 and 33 deaths in the prior inhaled treprostinil arm and prior placebo arm, respectively. With a conventional analysis, the HR for death was 0.71 (95% CI 0.46 to 1.10; p=0.1227). Both models demonstrated significant reductions in death associated with inhaled treprostinil treatment with HRs of 0.62 (95% CI 0.39 to 0.99; p=0.0483) and 0.26 (95% CI 0.07 to 0.98; p=0.0473) for the IPCW and RPSFT methods, respectively. CONCLUSION: Two independent modelling techniques that have been employed in the oncology literature both suggest a long-term survival benefit associated with inhaled treprostinil treatment in patients with PH-ILD.
引用
- Nathan SD, Johri S, Joly JM, et al. Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality. Thorax. 2024. PMID: 37979971. doi:10.1136/thorax-2023-220821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。